COPD (Chronic Obstructive Pulmonary Disease) is a life-threatening lung disease – it already affects more than 8% of adult humanity. Around 600 million people worldwide are said to have COPD.
COPD is a lung disease on the rise. With somatovitaltherapy (spirovitalization), COPD sufferers can alleviate their symptoms and experience new or more quality of life through this therapy (see testimonials / technical literature).
COPD (Chronic Obstructive Pulmonary Disease) is a collective term for chronic respiratory diseases. The main feature is the production of thick, purulent mucus in the lungs, which is difficult to cough up. Emphysema also often develops.
This leads to shortness of breath and and makes the simplest everyday activities enormously difficult for those affected. The probable cause of COPD is years of lung overload, e.g. by smoking or a job contaminated with fine dust. The extent to which the disease has progressed can be determined by the lung function test. This indicates, among other things, with the FEV1 value, how much air can be exhaled in one second. The results are divided into the so-called GOLD stages. In GOLD I, the symptoms are still not pronounced, while GOLD IV often means that the quality of life is extremely limited.
Lung damage is generally considered irreversible. Only individual symptoms can be reduced. Studies have impressively proven that spirovital therapy can achieve exceptionally good results, especially in lung diseases. In contrast to classical oxygen therapy, spirovitalization does not require a higher amount of oxygen but a higher quality. This allows the lungs to use oxygen better at the same performance. The results are often fewer colds, a easier coughing of the mucus and thus a freer breathing. A higher sense of well-being and more physical energy are the results. Many users even report that it is easier for them to walk and climb stairs again.
All body cells depend on the constant supply of oxygen. The oxygen content of the inhaled air, the functional efficiency of the airways, the diffusion capacity for oxygen from the alveoli into the vascular system, the transport via an intact vascular system and numerically sufficient and functional erythrocytes, an orderly transition of oxygen from the capillaries into the tissue, a permeable interstitium, an intact uptake into the individual cells, further transport into numerically sufficient and functional mitochondria and an optimal enzyme capacity for aerobic metabolism all play a major role. Disruptions are conceivable in many places. In the case of pulmonary emphysema, the problem is primarily due to the insufficient diffusion capacity for oxygen from the alveoli into the vascular system. In chronic bronchitis, inflammation and narrowing are added to the laying of bronchioles or bronchi. The full image of COPD is characterized by the additional formation and the “non-coughing” of tough mucus and increasing shortness of breath (oxygen distress). There is therefore no lack of oxygen in the breathing air, but the oxygen does not reach the target (mitochondria). Spirovitalisation reduces this deficit or at least partially eliminates the problem. By a short-term activation of the inhalation air before entering the respiratory tract, the initself sluggish molecular oxygen of the ambient air is activated (by formation of singlet oxygen, a stimulated but not radicalized form). This active state lasts only a fraction of a second. Even before the air is inhaled, the activated oxygen falls back to its original (ground) state. In this process, the previously absorbed energy is released again and released to the surrounding water, through which the breathing air is passed. With the inhalation of atmospheric oxygen, the airways are also fed to the energized water as a result of the water vapour saturation of the inhaled air, which initiates the desired increase in oxygen utilization. Due to this water-mediated energy transfer, on the one hand, a multiplication of 2,3 diphosphoglyzerate (2,3DPG), an important vitalizer of the intermediate phosphate group compensation in the conversion of 3PG into 2PG, an important step of the anaerobalactatic energy production in the erythrocytes, occurs on the one hand. In general, the concentration of the 2.3DPG is low, by spirovitalization it is demonstrably significantly increased. This allows 3PG to be converted to 2PG faster, which accelerates the transition from 1.3DPG to 3PG with an increase in the formation of ATP at the same time, with the result that the oxygen binding curve shifts to the right. Thus, with the same O2 saturation of the pO2 is increased or remains the same with lower O2 saturation of the pO2. This means an increased oxygen release to the environment, synonymous with a possible improvement in the utilization of oxygen, which is also manifested in an increase in AVDO2. By this mechanism, the observation seems to explain that spirovitalization, despite less diffusion of oxygen from the alveoli into the vascular system, can contribute to a sufficient oxygen supply to the individual organ systems. A second important effect of spirovitalization is the increase in immune competence. This is caused on the one hand by an increased activity of the white blood count, a reduced readiness for inflammation and a decrease in oxidative stress. Furthermore, spirovitalization (singuletoxygen) has been shown to intercept reactive oxygen types (ROS) or to a reduction in O2 radical formation. Irreversible damage to amino acids in the human body caused by atmospheric nitrate radicals is considered by experts to be a potential cause of respiratory disease.
- COPD with pulmonary emphysema, paO2 approx. 50 mmHg, duration O2 therapy so far rejected due to relatively good subjective condition, partial improvement after acupuncture, skeptical attitude towards spirovitalization, beginning with 3 x 10 or later 3 x 15 min tgl., 3 x / where., despite unfavorable weather, significant improvement of the subjective condition, increase of the paO2 rather slightly to 54 mmHg, overall positive judgment.
- Clinic diagnosis: infectious COPD with pulmonary emphysema, increased formation of tough mucus that is hard to cough, nocturnal coughing fits, after spirovitalization (up to 1 x 21 min) easier coughing of much and more liquid mucus, freer breathing.
- COPD with pulmonary emphysema, 71 a, severe deterioration in recent years, recent increasing shortness of breath, specialist treatment, after cold (wet cold weather) severe setback, after spirovitalization immediate improvement (no more shortness of breath, walking and climbing stairs again possible).
- COPD since about 12 a, side effects due to drug therapy (stomach, eyes), already after the first Spirovital application significant subjective and objective improvement (well-being, activity, less medications especially prednisone reduction, no more exacecations, no more colds, significant increase in oxygen saturation).
- COPD due to smoking and occupational asbestos exposure, 55 a, lack of air, lack of energy, walking distance 25 m, to nothing more able to achieve a significant improvement (more air, more energy) just a few days after the start of spirovitalization, increase of paO2 from under 70 to over 90 mmHg, improvement of lung function, even 1 a later no relapse, overall significant improvement (in the work process, on the home trainer, in terms of physical performance).
- COPD, 66 a, since 5 a in specialist treatment, since spirovitalization no more colds, more energy, better subjective condition, increase in oxygen content in the blood, less coughing, easier walking.
- COPD, 59 a, after spirovitalization short-term deterioration of subjective condition, then “amazing” improvement (climbing stairs without air shortage, raising energy levels, better sleep, no more fatigue).
- COPD, 78 a, strong smoker throughout life, before 4 a after pneumonia severe deterioration of subjective and objective condition (COPD), inhalation regulation, further deterioration to total immobility, after spirovitalization continuous increase of FEV1 from 0.59 l to 0.80 l and the FVC from 1.86 l to more than 3.10 l (increase by 210 and 1,150 ml respectively). There is a significant increase in subjective state and performance.
- COPD, 65 a, constant mucosa, additionally osteoporosis, rheumatoid arthritis, osteoarthritis; maximum walking distance approx. 200 m, lack of air, no appetite; Since Spirovitaluse reduction of inhaler applications, increase of peak flow (PEF) from 200 to 300 l/min, regular participation in lung sports without problems, more energy, more stamina, no more shortness of breath, improvement of blood circulation, easier coughing of more liquid mucus, improvement of sleep, more self-confidence, better condition.
In 2007, the scientific evaluation of declining opinions of Spirovitalend users and spirovital therapists in recent years was carried out, an overall insightful analysis. In 42 minutes, 163 diseases or disorders were reported (3.9 data per protocol). 77 percent of the complaints reported covered functional areas and 23 percent for organic areas. There was no age dependency on success, with figures ranging from 21 to 91 years. Sometimes there was a temporary deterioration, at the latest from the 7th day of application, clear subjective, usually also objective improvements occurred in all cases.
An evaluation of the end-user data on the effectiveness of spirovitalization in organic diseases showed that the device was also successfully used in respiratory diseases, detailed in bronchial asthma, sleep apnea, bronchitis, COPD and pulmonary emphysema. With regard to the functional disorders common in COPD, the end users had a positive assessment of spirovital therapy for energy status (performance, activity, resilience, strength, motivation), well-being (sleep quality, mood, breathing, digestion, pain, immune situation) and regeneration (deepening, acceleration, relaxation, pulse calming). The individual aspects applied to all end users, but the ranking was different depending on the individual starting position. There is therefore no doubt that many of the positive functional changes indicated also affected the clinical picture “COPD with pulmonary emphysema”.
The therapists also found effective use of spirovital therapy in respiratory diseases. Asthma and COPD were cited as special indications. According to the therapists, functional disorders associated with COPD and asthma can also be well influenced by spirovitalization, especially loss of performance, sleep disturbances and weakening of the immune system.
Dr. Klaus Jung / Dr. phil. Dinah Jung (2014) Handbook on Somatovital Therapy Part II: Studies and Practical Experiences – Monsenstein and Vannerdat
Why AIRNERGY at COPD?
Testimonials – The effect can be felt…
At the AIRNERGY headquarters, almost daily letters from convinced users who no longer want to miss their AIRNERGY cure and sometimes describe drastic improvements in their well-being and health status arrive.
Here is a selection of testimonials:
We will be happy to advise you without obligation & free of charge
firstname.lastname@example.org – +49 (0) 2242 – 9330 0